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Evaluation of
Potential Health Effects Associated with
Serum Polychlorinated Biphenyl Levels
by Paul A. Stehr-Green,* Edith Welty,t Greg Steele,* and
Karen Steinberg*
In late 1983, we conducted a cross-sectional epidemiologic study to evaluate persons at risk ofexposure
to three chemical waste sites by comparing clinical disease end points and clinical chemistry parameters
with serum polychlorinated biphenyls (PCB) levels. A total of 106 individuals participated in the study.
The only statistically significant finding in regard to self-reported, physician-diagnosed health problems
was a dose-response relationship between serum PCB levels and the occurrence of high blood pressure;
however, thisassociation failedtoachieve statistical significance (p = 0.08)whenwe controlledforpossible
confounding effects of both age and smoking. Serum triglyceride and cholesterol levels were also higher
in the group with elevated serum PCBs; additionally, there were isolated statistically significant corre-
lations of serum aspartate aminotransferase (SGOT) with serum lipid fraction-adjusted PCB level (r =
-0.21) and serum albumin (r = -0.24) and total bilirubin (r = 0.30) with serum PCB level. Although
the ranges of serum levels reported herein from exposures to PCBs in the general environment are lower
than those that have been associated with acute symptoms or illness in other studies, whether these levels
are associated with long-term health risks is not known. Associations ofsuch chronic, low-dose exposures
with observable health effects as suggested by this study must be evaluated further before any- final
conclusions can be drawn.
Background
Bloomington, a city of53,000 (1980 census) in Monroe
County, IN, has a complicated history of industrial
waste disposal compounded by unusual geologic fea-
tures that make the environment susceptible to pollu-
tion by such wastes. In late 1983, the Indiana State
Board of Health, in consultation with the Centers for
Disease Control (CDC), initiated a cross-sectional epi-
demiologic study ofexposure to and health effects from
polychlorinated biphenyls (PCBs) amongresidents near
three chemical waste sites. Primarily, we intended to
evaluate persons at high risk ofexposure to these waste
sites to determine if any of these individuals have ab-
normally elevated serum PCB levels and to identify
which environmental pathways containing PCBs might
have contributed most to producing abnormally ele-
vated levels of PCBs in human sera. A more detailed
site history and the results of these analyses are dis-
cussed in another report (1). Secondarily, we intended
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to compare clinical disease end points and clinical chem-
istry parameters with serum PCB levels; this report is
a summary of those findings.
Materials and Methods
We selected participants on the basis of screening
questionnaire data collected on all persons who had re-
sided within 1/2 mile ofthe three waste sites for at least
5 years. Since the primary purpose ofthe study was to
evaluate persons athigh riskofexposure tothese waste
sites, we first selected five to ten persons with the high-
est risk of exposure (i.e., with the greatest lifetime
number ofexposure opportunities) through each ofsev-
eral environmental pathways-e.g., eating contami-
nated native fish, playing or working in contaminated
soil areas. We also selected a group ofparticipants who
reported having had no occupational PCB exposures or
exposures to the waste sites. Finally, we selected a
group ofpersons by computer-generated random num-
bers from the universe of 995 persons identified in the
screening survey.
We attempted to contact persons selected for the
study in person or by telephone on at least three dif-
ferent occasions. Any person who was unwilling or un-
able to participate, or who was classified as lost to fol-STEHR-GREEN ET AL.
low-up, was replaced by the next eligible person until
we had recruited the sought-after number of partici-
pants in each category or until we had exhausted the
list ofeligible persons. Ifthe subjects were still willing
to participate, they were asked to fast for 12 hr before
their appointments for interview and phlebotomy. On
the day of the appointment, after obtaining informed
consent, 1 of 12 trained interviewers administered a
questionnaire to each participant that included items on
demographic characteristics, prescription druguse, and
historyofselected conditions ordiseaseswhichhadbeen
evaluated/diagnosed by aphysician. In addition, we col-
lected fasting blood specimens (30 mL for adults and 15
mL for children) using equipment and supplies, includ-
ing Vacutainer tubes, Wheaton vials, and Pasteur pi-
pettes (all eitherhexane-rinsed ordetermined tobe free
of PCBs by previous tests of blank tubes). Blood was
allowed to clot for30to 50min andwasthen centrifuged
for 10to20min. SerumwaspipettedintoWheatonvials,
which were then placed immediately on ice and kept
frozen and under strict chain of custody surveillance
until CDC laboratory personnel opened them.
Serum PCB levels were determined by the method
ofgas chromatography with electron capture (2). Qual-
ity assurance and quality control were strictly moni-
tored byanalyzingbench, blind, blank, and interference
controls and blind split duplicates with each analytical
run. Participants' sera were also analyzed for a 16-an-
alyte, liver-function profile run on a DuPont Automatic
Clinical Analyzer (ACA III). The analytes included:
gamma glutamyl transferase, aspartate aminotrans-
ferase (SGOT), triglyceride, cholesterol, alkaline phos-
phatase, total bilirubin, conjugated bilirubin, lactic de-
hydrogenase, urea nitrogen, albumin, total protein,
alanine aminotransferase (SGPT), uric acid, glucose,
high-density lipoprotein cholesterol, and immunoglob-
ulin G. Age- and sex-specific reference ranges for nor-
mal individuals were supplied by the manufacturer of
the ACA III.
Categorical data (e.g., measurements with a low ex-
pected proportion ofpositive results such as abnormally
elevated serum cholesterol levels) were examined via a
contingency table approach (X2 analysis) to determine
if differences existed between groups by using statis-
tical results for "normal" ranges specific to the labora-
tory and equipment employed in the analysis. When
appropriate, parametric statistics (e.g., analyses ofvar-
iance, t-tests for means) were used to compare group
means for serum analyte levels. To examine possibly
interactive and/or confounding associations, we used
multivariate techniques, such as analyses ofcorrelation
and logistic regression modeling, using apriori reason-
ing on variables to be included.
Since the serum levels ofPCBs and selected analytes
were lognormally distributed, all statistics are based on
these log-transformed values. Further, althoughthe to-
talnumberofparticipantswas 106, manyoftheanalyses
discussed below were conducted with a data set com-
prising slightly less than the total sample, because of
Table 1. Estimated excess prevalence of self-reported, physician-
diagnosed health problems by serum PCB level: Bloomington,
IN, 1984.
Relative risk (p-value)
¢ 20 (N=20) 3 30 (N=9) vs. ¢ 40 (N=5) vs.
Organ system or vs. < 20 ppb < 30 ppb < 40 ppb
diagnostic entity (N=94) (N= 105) (N= 109)
Liver 1.57 (0.43) 1.67 (0.49) 3.12 (0.31)
Urinary 0.78 (0.42) 0.43 (0.30) 0.81 (0.64)
Skin 1.14 (0.43) 0.92 (0.59) 1.12 (0.59)
Neurological 1.22 (0.38) 0.73 (0.46) 1.36 (0.47)
Eye 1.88 (0.21) 0.90 (0.70) 0.00 (0.51)
Respiratory 0.75 (0.58) 0.86 (0.59) 0.78 (0.62)
Generalized 0.72 (0.58) 0.83 (0.56) 1.56 (0.40)
problems
Cancer 0.00 (0.58) 0.00 (0.66) 0.00 (0.80)
High blood 1.63 (0.17) 1.73 (0.20) 2.34 (0.12)
pressure
missing values for either laboratory results or one or
more of the various demographic variables.
Results
Ofthe 106participants fromwhomweelicitedmedical
histories, 82 (77.4%) had self-reported, physician-di-
agnosed health problems for at least one ofthe 50 con-
ditions listed onthe questionnaire. Similarly, 80(75.5%)
participants reported having been diagnosed with
health problems in at least one ofthe nine selected tar-
get organ systems/conditions thought to be especially
susceptible to the effects of PCB exposure (i.e., high
bloodpressure, liverdisease, urinarytractdisease, der-
matologic problems, eye problems, neurological disor-
ders, respiratory problems, cancer, and selected met-
abolic disorders).
There were no statistically significant differences in
the prevalence ofany ofthese self-reported health out-
comevariables betweenthe20personswithserumPCB
levels > 20 ppb)* and the remaining 86 persons in the
study population with serum PCB levels < 20 ppb (see
Table 1). To elucidate possible dose-response relation-
ships, we conducted a series ofanalyses comparing the
health outcomes of persons with > 20, 30, and 40 ppb
of PCBs in serum with those whose serum levels were
lower than each of these respective cutoffs. A review
ofthese qualitative results suggests a serumPCB level-
response gradient for liver problems, high blood pres-
sure, and generalized disorders. When all health out-
comeswereevaluatedusinglogisticregression, onlythe
model with high blood pressure as the dependent var-
iable was statistically significant (p < 0.05); the contri-
bution of serum PCB level to the model was also sig-
nificant (p < 0.05). This significance remained even
when the model was controlled individually for age or
smoking (i.e., average number of cigarettes per day).
*Fromprevious results ofstatistical characterizations ofpopulation
groups in Michigan and South Carolina (3,4), we would expect that
95% ofanyrandomly selected populationsamplewillhave serumPCB
levels < 20 ppb; thus, we arbitrarily classified serum levels of ¢ 20
ppb as "abnormally elevated."
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Table 2. Correlation of log serum lipid fraction PCB level with
selected clinical chemistry results: Bloomington, IN, 1984.
Serum analyte N r p value
Aspartate aminotransferase 102 - 0.21 0.04
Triglyceride 105 - 0.04 0.70
Cholesterol 105 0.14 0.16
Total protein 104 - 0.06 0.51
Alanine aminotransferase 102 - 0.10 0.32
Glucose 102 0.06 0.58
High-density 102 - 0.06 0.56
lipoproteincholesterol
Immunoglobulin G 88 - 0.10 0.33
When all variables were included together inthe model,
however, overall significance dropped (p = 0.06), as did
the contribution of serum PCB level to the model (p =
0.08).
To gain a better understanding of the possible asso-
ciation of PCB exposure (as measured by serum PCB
level) with the chosen clinical chemistry parameters,
we examined serum analyte levels for 15 of the 16 an-
alytes in subjects' sera for which sufficient specimen
volumes were available; results for conjugated bilirubin
levels were considered to be invalid because of labo-
ratory quality control problems. We calculated corre-
lation coefficients between log-transformed serum PCB
levels and the serum analytes included in the ACA III
analyses. Since the laboratory analytical techniques
usedforselected analytes canbe affected bytotal serum
lipids, we correlated these variables with serum PCB
levels corrected for serum lipid fraction; results for
these eight analytes are presented in Table 2. Only
serum SGOT was statistically significantly inversely as-
sociated with serum lipid fraction-adjusted PCB level.
Table 3 contains the results of analyses conducted for
the remaining seven analytes. Serum albumin was sta-
tistically significantlyinverselycorrelated, andtotalbil-
irubin was directly correlated with serum PCB level.
We also compared mean serum levels for these 15
analytes between those persons with serum PCB levels
: 20 ppb versus those with levels < 20 ppb on the
clinical chemistry results (shown in Table 4). The only
significant differences in mean analyte values were
found for serum triglyceride and cholesterol. Similarly,
persons with serum PCBs : 20 ppb (see Table 5) had
a significant relative risk ofhaving abnormally elevated
(i.e., ± 2 standard deviations from the age- and sex-
specific reference laboratory "expected" or "normal"
Table 3. Correlation of log serum PCB level with selected
clinical chemistry results: Bloomington, IN, 1984.
Serum analyte N r p value
Gamma glutamyl 105 0.11 0.28
transferase
Alkaline phosphatase 105 - 0.12 0.21
Lactic dehydrogenase 102 - 0.01 0.88
Urea nitrogen 105 0.19 0.05
Albumin 105 - 0.24 0.02
Total bilirubin 105 0.30 < 0.01
Uric acid 103 0.17 0.08
means) serum triglyceride (RR = 4.8, p < 0.01) and
cholesterol (RR = 4.6, p = 0.02). All other differences
were not statistically significant.
To control for potential confounding, we performed
logistic regression analyses for abnormal serum analyte
values regressed on PCB levels and potential confound-
ers (e.g., age and alcohol consumption). The only model
that was statistically significant was one in which ab-
normally elevated serum glucose levels were regressed
on lipid fraction PCB level, age, and alcohol consump-
tion (X2[df=3] = 8.36, p = 0.04)-with subject's age
being the only independent variable contributing sig-
nificantly to the model (directly associated, p = 0.01).
Other models with an overall x2 statistic with 0.05 < p
< 0.10 were for: elevated SGOT regressed on lipid frac-
tion PCB level (inversely associated, p = 0.05), age
(directly associated, p = 0.03), and alcohol consumption
(p = 0.96); elevated urea nitrogen regressed on serum
PCB level (directly associated, p = 0.06) and age (p =
0.88); elevated SGPT regressed on lipid fraction PCB
level (inversely associated, p = 0.02), age (p = 0.15),
and alcohol consumption (p = 0.14); and elevated total
bilirubin regressed on serum PCB level (p = 0.25), age
(p = 0.72), and alcohol consumption (directly associ-
ated, p = 0.06).
Finally, weattempted toevaluatethedegreetowhich
the clinical chemistry results of these persons may re-
flect liver damage by convening a review panel ofthree
physicians with postdoctoral training and clinical ex-
perience in internal medicine. The reviewers, who were
"blinded" to the exposure status ofthe patients (i.e., a
priori groupings and serum PCB levels), were asked to
make a clinical judgment on each patient in regard to
the presence of "possible (or probable) liver disease
which would require follow-up clinical evaluation" on
the basis of review of the laboratory slips. In all, 14
patients were judged by at least two of the three re-
viewers to have "possible liver disease." Ofthose with
serum PCB levels
- 20 ppb, 21.1% (4/19) were so classi-
fied as showing signs consistent with possible liver dis-
ease versus 11.5% (10/87) of those with serum PCB
levels < 20 ppb. This corresponds to a relative risk of
1.62, which was not statistically significant (p = 0.22).
Discussion
The evidence for a direct association of serum PCB
level with hypertension is perhaps the most significant
finding ofthis study. Health effects reported for work-
ers exposed to PCBs have not included this association
but have recorded excess prevalence of chloracne and
other skin irritations, digestive disturbances, eye irri-
tation, and impotence (5). However, in one study of
nonoccupationally exposedpersonswho ate fish contam-
inated with PCBs, an association between serum PCB
level and diastolic blood pressure was demonstrated
which persisted afterpotentially confoundingvariables,
including age, were taken into account (6). Consistent
with this previous report and others in the literature,
our data support a dose-response relationship ofserum
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Table 4. Mean clinical chemistry results by serum PCB level: Bloomington, IN, 1984.
Unit of Mean values (standard deviation)
Analyte measure > 20 ppb serum PCB N < 20 ppb serum PCB N t-test
Gamma glutamyl
transferase U/L 28.7 (25.7) 18 27.6 (28.7) 87 (p = 0.88)
Aspartate amino-
transferase U/L 36.0 (7.8) 15 38.2 (12.3) 87 (p = 0.50)
Triglyceride mg/dL 264.9 (21.9) 18 129.7 (71.5) 87 (p = 0.02)*
Cholesterol mg/dL 245.1 (55.0) 19 190.9 (46.3) 87 (p <0.01)t
Alkaline
phosphatase U/L 105.7 (33.7) 18 105.9 (57.6) 87 (p = 0.98)
Lactic
dehydrogenase U/L 125.6 (24.5) 16 133.1 (33.9) 86 (p = 0.40)
Urea nitrogen mg/dL 14.4 (6.0) 18 12.9 (3.6) 87 (p = 0.32)
Albumin g/dL 4.3 (1.0) 18 4.4 (0.3) 87 (p = 0.17)
Total protein g/dL 6.5 (0.7) 17 6.9 (0.6) 87 (p = 0.16)
Alanine amino-
transferase U/L 14.6 (5.6) 16 14.8 (8.4) 86 (p = 0.98)
Total bilirubin mg/dL 1.2 (1.5) 18 0.7 (0.4) 87 (p = 0.10)
Uric acid mg/dL 5.8 (1.6) 18 5.3 (1.5) 85 (p = 0.27)
Glucose mg/dL 118.0 (42.9) 18 103.3 (38.6) 85 (p = 0.15)
High-density
lipoprotein-cholesterol mg/dL 38.1 (9.2) 16 40.4 (12.0) 86 (p = 0.47
Immunoglobulin G mg/dL 1073.3 (209.7) 15 1072.2 (211.6) 74 (p = 0.99)
*Different from group with serum PCB ¢ 20 ppb at 5% level of significance.
tDifferent from group with serum PCB a 20 ppb at 1% level of significance.
Table 5. Estimated excess prevalence of abnormal clinical
chemistry results by serum PCB level Bloomington, IN, 1984.
Relative risk
:20 ppb vs. -20 ppb
Laboratory analyte serum PCB N
Gamma glutamyl transferase,
elevated:a 0.94 (p = 0.70) 97
Aspartate aminotransferase,
elevated: 1.52 (p = 0.30) 94
Triglycerides
Elevated: 4.83 (p < 0.01) 105
Decreased:b 0.00 (p = 0.69) 105
Cholesterol
Elevated: 4.57 (p = 0.02) 106
Decreased: 0.00 (p = 0.45) 105
Alkaline phosphatase, elevated: 0.81 (p = 0.56) 105
Lactic dehydrogenase, elevated: 0.00 (p = 0.35) 102
Urea nitrogen, elevated: 9.66 (p = 0.08) 105
Albumin, decreased; NCC (p = 1.00) 105
Total protein, decreased: 1.71 (p = 0.20) 104
Alanine aminotransferase, ele- 0.00 (p = 0.50) 102
vated:
Total bilirubin elevated: 4.83 (p = 0.06) 105
Uric acid, elevated: 1.72 (p = 0.16) 95
Glucose
Elevated: 2.02 (p = 0.10) 103
Decreased: 0.00 (p = 0.83) 103
High-density lipoprotein-cholesterol
Elevated: 0.00 (p = 0.84) 94
Decreased: 1.50 (p = 0.15) 94
Immunoglobulin G
Elevated: 1.23 (p = 0.61) 89
Decreased NC (p = 1.00) 89
a> 2 standard deviations above reference laboratory mean value.
b < 2 standard deviations below reference laboratory mean value.
'No cases in both study groups.
PCB levels and the occurrence of high blood pressure.
The pathophysiology of this relationship, whether op-
erating through PCB effects on renal function or en-
hanced progression of atherosclerotic processes, re-
mains unclear. This association should be further
evaluated in animal toxicologic studies, as well as in
larger epidemiologic studies of actual measured blood
pressures in which potentially important confounding
factors (such as dietaryhabits and socioeconomic status)
can be adequately controlled.
Other studies have shown an elevation of serum cho-
lesterol, triglyceride, and high density lipoprotein with
elevated serum PCB levels (5,7,8). Consistent with
these studies, we found evidence ofhigher mean levels,
as well as a greater prevalence of clinically elevated
serum triglyceride and cholesterol in the group with
serum PCB levels , 20 ppb. These results may offer
further evidence for an alteration in lipid metabolism
due to PCB exposures. However, the results may be
spuriousbecausepersonswithelevated serumlipidsdue
to other, unrelated factors may be more likely to have
higher measured serum PCB levels because of the li-
pophilic nature ofPCBs (9). In addition, because oflim-
itations of the relatively small sample size and the un-
availability of pertinent data, we could not control for
all potentially important confounders.
Results of several studies of occupationally exposed
persons have shown a direct association between serum
PCB levels and gamma glutamyl transpeptidase and
SGOT and an inverse association with bilirubin (10);
these studies apparently show that PCBs are inducers
of microsomal enzymes in man, but do not show con-
clusively that they cause liver damage. We could not
corroborate these results with the data collected in this
study. In fact, the inverse correlation of serum PCB
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level with SGOT which we found contradicts these pre-
vious animal toxicological and human studies; however,
this finding is biologically implausible except in cases of
gross hepatic pathology, which we did notobserve. Sim-
ilarly, ourfinding ofa statistically significant direct cor-
relation oftotalbilirubin with serumPCB levels isprob-
ably spurious. The other statistically significant clinical
chemistryfindings-i.e., thedirect correlationbetween
serum PCB levels and serum uric acid levels, as well
as the inverse correlation ofserum albumin with serum
PCB levels, are consistent with liver disease but were
not corroborated in further analyses.
Summary and Conclusions
In summary, our results were suggestive of an in-
creased risk of hypertension and altered lipid metabo-
lism in persons exposed to environmental PCBs. Oth-
erwise, we found no evidence of adverse health effects
in other key target organs that included the skin and
the nervous system. Similarly, no clear patterns ofclin-
ical pathology are evidenced from the clinical chemistry
results. Our failure to demonstrate a significant excess
ofadverse health effects due toPCB exposuremayhave
been due tothe relatively small sample size inthis study
(i.e., low statistical power), our inability to detect ef-
fects with long latency periods, or missed subtle health
effects or symptoms that had not been diagnosed by a
physician (and, therefore, not recorded); alternatively,
it may be that there are no detectable adverse health
effects from chronic, low-dose exposures to environ-
mental PCBs.
The ranges of serum levels reported herein from ex-
posures to PCBs in the general environment are lower
than those that have been associated with acute symp-
toms orillnessinotherstudies, usuallyinoccupationally
exposed cohorts; furthermore, whether these levels are
associated with long-term health risks is not known.
The apparent overall lack in this study of positive as-
sociations of such chronic, low-dose exposures with ob-
servable health effects (with the possible exception of
increased risk of high blood pressure and altered lipid
metabolism) must be evaluated further before any con-
clusions can be drawn. Because ofthis uncertainty, the
need continues for appropriate remedial action to pre-
vent further exposure to this and other similar popu-
lations.
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